Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6853744 | 0.91 | — | — | |
| SCHEMBL7162914 | 0.82 | EPHX2 (0.31) | EPHX2 | |
| SCHEMBL7068833 | 0.77 | — | — | |
| SCHEMBL2757819 | 0.71 | ARG1 (0.54) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL7072467 | 0.71 | GGT1 (0.35) | — | |
| SCHEMBL7069203 | 0.71 | GGT1 (0.35) | — | |
| SCHEMBL2712951 | 0.70 | ARG1 (0.53) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL28334310 | 0.70 | ARG1 (0.53) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL7072192 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL2713261 | 0.69 | ARG1 (0.51) | KDM4EMAPK1HIF1APAOXADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317417-A2 | 2-AMINO-2-ALKYL-3 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020072630-A1 | 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2002-06-13 | — | — | US | claimed |
| WO-2002022558-A2 | 2-AMINO-2-ALKYL-3 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2002-03-21 | — | — | WO | claimed |
| US-20020072630-A1 | 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072630-A1 | 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PTGIS, NOS3, ALOX12 | KDM4E 1922/4885MAPK1 1695/4885HIF1A 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.